- Home
- KZR vs CNC Comparison
KZR vs CNC Comparison
Compare KZR & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | CNC |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 18.7B |
| IPO Year | 2018 | 2001 |
Fundamental Metrics
Financial Performance| Metric | KZR | CNC |
|---|---|---|
| Price | $6.33 | $39.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 17 |
| Target Price | $6.00 | ★ $40.06 |
| AVG Volume (30 Days) | 35.9K | ★ 7.2M |
| Earning Date | 11-12-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $167,680,000,000.00 |
| Revenue This Year | N/A | $32.54 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.57 |
| 52 Week Low | $3.53 | $25.08 |
| 52 Week High | $6.95 | $66.81 |
Technical Indicators
Market Signals| Indicator | KZR | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 54.92 |
| Support Level | $6.16 | $38.02 |
| Resistance Level | $6.33 | $39.91 |
| Average True Range (ATR) | 0.10 | 1.26 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 80.00 | 42.32 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.